Company name
EvlaBio
Company profile
EvlaBio is developing a first-in-class therapy to address Left Ventricular Hypertrophy (LVH) in the setting of chronic kidney disease (CKD), a critical unmet medical need affecting millions worldwide. CKD affects more than 10% of the global population. LVH prevalence increases with CKD progression, affecting approx. 30-45% of patients in early stages and up to 80% of patients on dialysis. Cardiovascular disease remains the leading cause of mortality in this population.
Date, time and room information
Monday, May 4, 15:30 - 15:45, room Singapore
Category
Emerging biotech company
Title of the presentation
First-in-Class Anti-FGFR4 Therapy for CKD-Associated Cardiac Disease
Speaker information
| Name | Position | Institution |
|---|---|---|
| Wenzel von der Heydte | CEO | EvlaBio |
